Introduction
To review the current best evidence regarding treatment of AVWS, we first addressed the question of whether AVWS is associated with increased risk of bleeding and next, whether bleeding is effectively treated with intravenous immunoglobulins (IVIg), steroids, VWF concentrates, or treatment of the underlying disorder. We performed a comprehensive review of the published literature indexed on the OVID Medline database using the following search terms: ("von We reviewed the titles, abstracts and full text versions of these 576 hits to determine which articles provided evidence related to AVWS in childhood. Many were excluded for the following reasons: 42 articles because they dealt exclusively with problems of platelet or vascular function, 188 because they dealt only with congenital hemophilia or inherited von Willebrand disease (VWD), 115 because they dealt with TTP/HUS, 41 because they were concerned about hypercoagulable states, 87 because they dealt with other factor deficiencies, 21 because they dealt with problems of pregnancy, 55 because they contained evidence only related to adults, and 11 because they had no information relating to AVWS. We identified 24 articles from this search that provide evidence related to AVWS in childhood. From the references of these articles we identified 18 additional articles. The evidence is summarized and graded according to published guidelines 1 .
Hereditary low VWF activity with bleeding symptoms has an estimated prevalence of 1% in the population and 1 person in 10,000 may be diagnosed with VWD 2 . In contrast, AVWS is a rare acquired disorder with a prevalence estimated to be 0.04% 3 , although this may be an underestimate 4 . The pathophysiology of AVWS is heterogeneous and includes antibody mediated destruction, decreased production, adsorption of VWF to tumor or destruction from sheer stress 5, 6 . (Figure 1 ) Common etiologies in adults, such as lymphoproliferative disorders and myeloproliferative diseases 7 , are uncommon in children 8 while AVWS associated with cardiovascular disease is common in both adults and children. In contrast, neoplasia (Wilms' Tumor), hypothyroidism, and auto-immunity are more often associated with AVWS in children. Interestingly, the first reported case of AVWS was in a 13 year old boy with systemic lupus erythematosus (SLE) 9 . AVWS should be considered in children with bleeding and AVWSassociated disorders and should also be considered in asymptomatic children with AVWSassociated disorders who are schedule to undergo a procedure. Although, AVWS is uncommon it can complicate management of the underlying disorders and there is limited evidence for the management of bleeding symptoms in children with AVWS. We recommend that children with an underlying diagnosis associated with AVWS have VWF antigen, ristocetin cofactor activity, factor FVIII activity and VWF multimer analyses performed in the setting of bleeding symptoms or situations that present a high-risk of bleeding such as surgical interventions. While abnormalities identified by this testing could represent underlying congenital VWD, the correction of these abnormalities upon treatment of the AVWS-associated disorder strongly suggests a diagnosis of AVWS. 
Treatment of AVWS caused by auto-antibodies
There have been several reports of AVWS in children with SLE or children who later went on to develop SLE [9] [10] [11] [12] . Because the onset of full-blown SLE may lag behind the diagnosis of VWF defects, this should be considered in children diagnosed with VWD in the absence of a clear family history. Patients with AVWS associated with SLE have been successfully treated with DDAVP, factor infusion and immunosuppressive regimens. The offending antibodies may target functional or non-functional epitopes of circulating VWF and result in production of VWFimmune complexes that are rapidly cleared by the reticuloendothelial system, resulting in shortened VWF half-life. It is recommended that prior to prophylaxis for high-risk situations, pharmacokinetics of DDAVP or infused VWF be evaluated since patients with inhibitory antibodies detectable in plasma mixing studies may have poor responses to DDAVP 13 . IVIg has also been used effectively in patients with auto-antibody-mediated AVWS 8 .
Treatment of AVWS caused by adsorption to malignancy
AVWS has been reported in association with multiple malignancies, including lymphomas, osteosarcoma, and primitive neuroectodermal tumor (PNET). Wilms' Tumor is the malignancy most commonly association with AVWS, with a prevalence of 8% in newly diagnosed Wilms' tumor patients 14 . In these malignancies, VWF is adsorbed to tumor tissue and thereby sequestered from the circulation. Because these patients often require resection of the tumor, treatment is frequently required to prevent surgical bleeding [15] [16] [17] . Although based on a very small number of treated patients, published reports describe use of DDAVP and replacement of VWF. However, the half-life of VWF is decreased as the infused factor also adsorbs to the tumor. It is recommended that a DDAVP trial be performed prior to therapeutic use to determine the patient's response 14 . IVIg has also been used as a treatment for AVWS in Wilms' Tumor with success in 2 of 2 reported cases 8 . Removal and/or treatment of the underlying cancer results in remission of AVWS.
Treatment of AVWS caused by a hypothyroidism
Hypothyroidism appears to cause decreases in production of VWF and causes a mild mucocutaneous bleeding phenotype [18] [19] [20] [21] . Inhibitory antibodies to VWF are not seen in AVWS caused by hypothyroidism 22, 23 . Low levels of VWF may be a common finding in pediatric patients with hypothyroidism but often with minimal or no symptoms 24 . AVWS seen in children with hypothyroidism resolves with replacement of thyroxine. However, prophylactic DDAVP should be considered prior to thyroid biopsy or other surgery in these patients prior to correction of the thyroid hormone deficiency. A study of 131 patients diagnosed with VWD who were subsequently screened for hypothyroidism identified 8 patients in whom VWF levels normalized after thyroid hormone replacement 25 .
Treatment of AVWS caused by a cardiovascular disease
The best-studied cause of AVWS in childhood is increased shear stress from congenital heart lesions. Aortic stenosis 26, 27 , pulmonary stenosis 28 patent ductus arteriosus 29 , ventricular and atrial septal defects 27 have all been associated with AVWS. Recently, with the increasing use of ventricular assist devices in children there have been cases of AVWS related to high shearing caused by these mechanical devices 30 . High-shear stress results in availability of ADAMTS-13 cleavage sites and reduction of high-molecular weight multimers as is seen in some patients with congenital VWD 2A. Patients with congenital heart disease associated AVWS are at increased risk of significant perioperative bleeding and intracranial hemorrhage which could possibly be exacerbated with concomitant aspirin use 31 . Correction of the underlying heart lesion usually results in remission of AVWS. DDAVP and replacement of VWF For personal use only. on October 22, 2017. by guest www.bloodjournal.org From may reduce bleeding symptoms in children with high-shear stress lesions and reduced levels of high-molecular weight multimers. DDAVP has been shown in a double-blind placebo controlled trial to reduce bleeding in adults undergoing aortic valve replacement for aortic stenosis 32 , although only a small subset of these patients had proven AVWS. Further the risk of DDAVPinduced fluid overload and hyponatremia in the setting of these major surgeries should always be considered.
Treatment of Drug induced AVWS
AVWS has been reported rarely with the use of griseofulvin, ciprofloxacin, tetracycline, thrombolytic agents and hydroxyethyl starch 33 . AVWS, thrombocytopenia and other coagulation abnormalities have been frequently associated with valproic acid therapy, with AVWS incidence as high as 20-67% [34] [35] [36] [37] [38] . However, larger more recent studies have suggested the incidence may be much lower 39 . While increased proteolysis has been implicated as a cause of AVWS with ciprofloxacin, the mechanism for AVWS caused by valproic acid has remained elusive. It has been recommended that perioperative management or treatment of bleeding complications in AVWS associated with valproic acid therapy should employ VWF concentrates only as DDAVP may increase the risk of seizures in these patients 38 .
Conclusion
For our 3 years old patient described in the vignette the likely diagnosis is AVWS caused by adsorption of VWF to a Wilms' tumor, although an underlying VWD 2A cannot be excluded based on the vignette. Appropriate therapy would include measurement of response to VWF replacement therapy prior to surgery and infused VWF concentrates perioperatively to normalize VWF levels. Resection and therapy for the underlying Wilms' tumor should result in remission of this patient's AVWS. (Table 1) 
Evidence-Based Recommendations

IVIg may be used as an ancillary treatment in AVWS mediated by immune destruction of VWF (2c).
Valproic Acid therapy related AVWS should be treated with VWF concentrates and DDAVP should be avoided as it may precipitate seizures (2c)
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